MA61732A1 - Ouvreur de canaux potassiques sensibles à la tension destiné à être utilisé dans le traitement de l'anhédonie - Google Patents
Ouvreur de canaux potassiques sensibles à la tension destiné à être utilisé dans le traitement de l'anhédonieInfo
- Publication number
- MA61732A1 MA61732A1 MA61732A MA61732A MA61732A1 MA 61732 A1 MA61732 A1 MA 61732A1 MA 61732 A MA61732 A MA 61732A MA 61732 A MA61732 A MA 61732A MA 61732 A1 MA61732 A1 MA 61732A1
- Authority
- MA
- Morocco
- Prior art keywords
- voltage
- anhedonia
- potassium channel
- channel opener
- treatment
- Prior art date
Links
- 208000007415 Anhedonia Diseases 0.000 title abstract 2
- 239000004036 potassium channel stimulating agent Substances 0.000 title abstract 2
- 102000008396 voltage-gated potassium channel activity proteins Human genes 0.000 title abstract 2
- 108040002559 voltage-gated potassium channel activity proteins Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Ignition Installations For Internal Combustion Engines (AREA)
- Electrotherapy Devices (AREA)
- Shovels (AREA)
Abstract
La présente divulgation a pour objet, entre autres, le n-[ 4- ( 6-fluoro-3,4-dihydro-ih-isoquinolin-2-yl)-2,6-diméthylphényl]-3,3- diméthylbutanamide (composé a), qui est un ouvreur de canaux potassiques sensibles à la tension, destiné à être utilisé dans une méthode de traitement de l'anhédonie chez un sujet, tel qu'un être humain. En outre, la présente divulgation a pour objet divers moyens améliorés d'administration du composé a.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163147742P | 2021-02-09 | 2021-02-09 | |
| PCT/US2022/015854 WO2022173855A1 (fr) | 2021-02-09 | 2022-02-09 | Ouvreur de canaux potassiques sensibles à la tension destiné à être utilisé dans le traitement de l'anhédonie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA61732A1 true MA61732A1 (fr) | 2024-01-31 |
Family
ID=80445983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA61732A MA61732A1 (fr) | 2021-02-09 | 2022-02-09 | Ouvreur de canaux potassiques sensibles à la tension destiné à être utilisé dans le traitement de l'anhédonie |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11957675B2 (fr) |
| EP (1) | EP4291189A1 (fr) |
| JP (1) | JP2024508660A (fr) |
| KR (1) | KR20240004241A (fr) |
| CN (1) | CN116847843A (fr) |
| AU (1) | AU2022220675A1 (fr) |
| CA (1) | CA3207191A1 (fr) |
| CL (1) | CL2023002321A1 (fr) |
| IL (1) | IL304920A (fr) |
| MA (1) | MA61732A1 (fr) |
| MX (1) | MX2023009314A (fr) |
| TW (1) | TW202245744A (fr) |
| WO (1) | WO2022173855A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220288057A1 (en) * | 2021-02-09 | 2022-09-15 | Xenon Pharmaceuticals Inc. | Conjoint therapy for treating seizure disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009535370A (ja) | 2006-05-02 | 2009-10-01 | クリス ルントフェルト | ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤 |
| DK2061465T3 (da) | 2006-08-23 | 2013-07-08 | Valeant Pharmaceuticals Int | Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer |
| US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| NZ582942A (en) * | 2007-08-01 | 2011-09-30 | Lundbeck & Co As H | Use of kncq potassium channel openers for treating attention deficit hyperactivity disorder (adhd) or aggression |
| RS64922B1 (sr) * | 2018-05-11 | 2023-12-29 | Xenon Pharmaceuticals Inc | Postupci za povećanje bioraspoloživosti i izloženosti otvaraču naponom kontrolisanih kalijumskih kanala |
| TW202128627A (zh) | 2019-10-10 | 2021-08-01 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| CA3155812A1 (fr) | 2019-11-08 | 2021-05-14 | Cynthia Louise HARDEN | Methodes de traitement de troubles depressifs |
| WO2021113802A1 (fr) * | 2019-12-06 | 2021-06-10 | Icahn School Of Medicine At Mount Sinai | Procédé de traitement avec des activateurs de canaux kcnq |
-
2022
- 2022-02-09 CN CN202280014279.1A patent/CN116847843A/zh active Pending
- 2022-02-09 WO PCT/US2022/015854 patent/WO2022173855A1/fr active Application Filing
- 2022-02-09 JP JP2023547490A patent/JP2024508660A/ja active Pending
- 2022-02-09 EP EP22705687.6A patent/EP4291189A1/fr active Pending
- 2022-02-09 MA MA61732A patent/MA61732A1/fr unknown
- 2022-02-09 US US17/668,340 patent/US11957675B2/en active Active
- 2022-02-09 IL IL304920A patent/IL304920A/en unknown
- 2022-02-09 AU AU2022220675A patent/AU2022220675A1/en active Pending
- 2022-02-09 MX MX2023009314A patent/MX2023009314A/es unknown
- 2022-02-09 KR KR1020237030629A patent/KR20240004241A/ko unknown
- 2022-02-09 CA CA3207191A patent/CA3207191A1/fr active Pending
- 2022-02-09 TW TW111104798A patent/TW202245744A/zh unknown
-
2023
- 2023-08-07 CL CL2023002321A patent/CL2023002321A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11957675B2 (en) | 2024-04-16 |
| KR20240004241A (ko) | 2024-01-11 |
| CL2023002321A1 (es) | 2024-03-08 |
| WO2022173855A1 (fr) | 2022-08-18 |
| EP4291189A1 (fr) | 2023-12-20 |
| AU2022220675A1 (en) | 2023-09-21 |
| CA3207191A1 (fr) | 2022-08-18 |
| IL304920A (en) | 2023-10-01 |
| MX2023009314A (es) | 2023-08-16 |
| CN116847843A (zh) | 2023-10-03 |
| US20220265634A1 (en) | 2022-08-25 |
| TW202245744A (zh) | 2022-12-01 |
| JP2024508660A (ja) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA61732A1 (fr) | Ouvreur de canaux potassiques sensibles à la tension destiné à être utilisé dans le traitement de l'anhédonie | |
| MA38898A1 (fr) | Combinaison de facteurs épigénétiques et de composés bispécifiques ciblant cd33 et cd3 dans le traitement de la leucémie myéloïde | |
| Okhuysen et al. | Cryptosporidium virulence determinants–are we there yet? | |
| MA31894B1 (fr) | Composes organiques | |
| TN2009000018A1 (fr) | Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques | |
| MA27348A1 (fr) | Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| MA31319B1 (fr) | Dérivés de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MXPA05006569A (es) | Compuestos que inhiben la proteina cinasa-2 activada por la proteina cinasa activada por el mitogeno. | |
| MD3790548T2 (ro) | Metode de îmbunătățire a biodisponibilității și expunerii activatorului de canale de potasiu voltaj-dependente | |
| CA2335903A1 (fr) | Nouvelle cyclosporine ayant un profil d'activite ameliore | |
| EA200601239A1 (ru) | Замещённые хинолиновые соединения | |
| MA28093A1 (fr) | Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine | |
| MA31776B1 (fr) | Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé | |
| CN1119854A (zh) | 用作抗肿瘤药剂的酰基富烯类似物 | |
| FR2385734A1 (fr) | Substance antitumorale obtenue par culture de mycelium | |
| Garzón et al. | The Trypanosoma brucei gambiense secretome impairs lipopolysaccharide-induced maturation, cytokine production, and allostimulatory capacity of dendritic cells | |
| FR3080114B1 (fr) | Diglycolamides dissymetriques amphiphiles et leur utilisation pour extraire les terres rares de solutions aqueuses acides | |
| CA2548111A1 (fr) | Solutions de cipc et d'un terpene ou d'une huile terpenique et leurs utilisations pour le traitement antigerminatif de bulbes ou tubercules | |
| MA27956A1 (fr) | Traitement enzymatique d'une masse constituee d'olives et de constituants d'olives | |
| MA54318B1 (fr) | Formulations de capsules | |
| Pereira-Filho et al. | Evasion of the complement system by Leishmania through the uptake of C4bBP, a complement regulatory protein, and probably by the action of GP63 on C4b molecules deposited on parasite surface | |
| MA56607A1 (fr) | Méthodes de traitement de troubles dépressifs | |
| TNSN04200A1 (fr) | Peptides et leur application en therapeutique | |
| ATE178074T1 (de) | Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes |